224 related articles for article (PubMed ID: 28638726)
1. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.
Pedersen MH; Hood BL; Beck HC; Conrads TP; Ditzel HJ; Leth-Larsen R
Oncoimmunology; 2017; 6(5):e1305531. PubMed ID: 28638726
[TBL] [Abstract][Full Text] [Related]
2. CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
Pedersen MH; Hood BL; Ehmsen S; Beck HC; Conrads TP; Bak M; Ditzel HJ; Leth-Larsen R
Int J Cancer; 2019 Feb; 144(3):631-640. PubMed ID: 30110125
[TBL] [Abstract][Full Text] [Related]
3. A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer.
Stewart RL; Updike KL; Factor RE; Henry NL; Boucher KM; Bernard PS; Varley KE
Cancer Res; 2019 Jul; 79(13):3466-3478. PubMed ID: 31048497
[TBL] [Abstract][Full Text] [Related]
4. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
[TBL] [Abstract][Full Text] [Related]
5. Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.
Forero A; Li Y; Chen D; Grizzle WE; Updike KL; Merz ND; Downs-Kelly E; Burwell TC; Vaklavas C; Buchsbaum DJ; Myers RM; LoBuglio AF; Varley KE
Cancer Immunol Res; 2016 May; 4(5):390-9. PubMed ID: 26980599
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
7. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling.
Park IA; Hwang SH; Song IH; Heo SH; Kim YA; Bang WS; Park HS; Lee M; Gong G; Lee HJ
PLoS One; 2017; 12(8):e0182786. PubMed ID: 28817603
[TBL] [Abstract][Full Text] [Related]
8. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419.
Routh ED; Van Swearingen AED; Sambade MJ; Vensko S; McClure MB; Woodcock MG; Chai S; Cuaboy LA; Wheless A; Garrett A; Carey LA; Hoyle AP; Parker JS; Vincent BG; Anders CK
Front Oncol; 2022; 12():818693. PubMed ID: 35992833
[TBL] [Abstract][Full Text] [Related]
11. EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer.
Nikas I; Giaginis C; Petrouska K; Alexandrou P; Michail A; Sarantis P; Tsourouflis G; Danas E; Pergaris A; Politis PK; Nakopoulou L; Theocharis S
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204461
[TBL] [Abstract][Full Text] [Related]
12. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
13. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer.
Feng W; Li Y; Chu J; Li J; Zhang Y; Ding X; Fu Z; Li W; Huang X; Yin Y
Cancer Med; 2018 Oct; 7(10):5130-5144. PubMed ID: 30239174
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
15. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
[TBL] [Abstract][Full Text] [Related]
16. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
17. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
18. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival.
Tozbikian G; Brogi E; Kadota K; Catalano J; Akram M; Patil S; Ho AY; Reis-Filho JS; Weigelt B; Norton L; Adusumilli PS; Wen HY
PLoS One; 2014; 9(12):e114900. PubMed ID: 25506917
[TBL] [Abstract][Full Text] [Related]
19. Distinct Gene Expression Profiles of Matched Primary and Metastatic Triple-Negative Breast Cancers.
Kaur J; Chandrashekar DS; Varga Z; Sobottka B; Janssen E; Kowalski J; Kiraz U; Varambally S; Aneja R
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626050
[TBL] [Abstract][Full Text] [Related]
20. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
